US10912771 — Methods for the administration of certain VMAT2 inhibitors
Method of Use · Assigned to Neurocrine Biosciences Inc · Expires 2037-10-10 · 11y remaining
What this patent protects
This patent protects methods of administering valbenazine tosylate to patients being treated with a strong CYP3A4 inducer.
USPTO Abstract
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3076 |
— | valbenazine-tosylate |
U-3055 |
— | valbenazine-tosylate |
U-1995 |
— | valbenazine-tosylate |
U-3055 |
— | valbenazine-tosylate |
U-3055 |
— | valbenazine-tosylate |
U-3076 |
— | valbenazine-tosylate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.